Delstrigo

Delstrigo is a combination medication containing Lamivudine, Doravirine, and Tenofovir Disoproxil, used for managing HIV. This oral medication is designed to support HIV treatment regimens, offering a convenient once-daily option.

Delstrigo is primarily used as part of antiretroviral therapy (ART) for individuals with HIV. It combines three active ingredients to help manage the virus and support immune system health. The medication is intended for long-term use under medical supervision. Delstrigo is not a cure for HIV but helps control the virus, reducing the risk of complications and transmission.

Common effects of Delstrigo may include headaches, dizziness, nausea, and fatigue. Some individuals may experience changes in mood or sleep patterns. These effects vary and are not experienced by everyone. If any effects are severe or persistent, it is important to consult a healthcare provider.

Delstrigo should be handled with care, following the guidance of a healthcare professional. It is important to disclose all medications and health conditions to avoid potential interactions or complications. Regular monitoring and follow-ups are recommended to ensure the medication's effectiveness and safety.

Delstrigo may interact with other medications, including certain antacids, antibiotics, and antifungal drugs. It is important to inform healthcare providers about all medications, supplements, and herbal products being used. Alcohol and other substances may also affect the medication's performance.